Correlation Between Spero Therapeutics and Cue Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Spero Therapeutics and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spero Therapeutics and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Spero Therapeutics and Cue Biopharma, you can compare the effects of market volatilities on Spero Therapeutics and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spero Therapeutics with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spero Therapeutics and Cue Biopharma.

Diversification Opportunities for Spero Therapeutics and Cue Biopharma

-0.37
  Correlation Coefficient

Very good diversification

The 3 months correlation between Spero and Cue is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Spero Therapeutics and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Spero Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spero Therapeutics are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Spero Therapeutics i.e., Spero Therapeutics and Cue Biopharma go up and down completely randomly.

Pair Corralation between Spero Therapeutics and Cue Biopharma

Given the investment horizon of 90 days Spero Therapeutics is expected to generate 0.37 times more return on investment than Cue Biopharma. However, Spero Therapeutics is 2.7 times less risky than Cue Biopharma. It trades about 0.03 of its potential returns per unit of risk. Cue Biopharma is currently generating about 0.01 per unit of risk. If you would invest  103.00  in Spero Therapeutics on August 25, 2024 and sell it today you would earn a total of  13.00  from holding Spero Therapeutics or generate 12.62% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Spero Therapeutics  vs.  Cue Biopharma

 Performance 
       Timeline  
Spero Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Cue Biopharma 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Cue Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point.

Spero Therapeutics and Cue Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Spero Therapeutics and Cue Biopharma

The main advantage of trading using opposite Spero Therapeutics and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spero Therapeutics position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.
The idea behind Spero Therapeutics and Cue Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world